These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 5527168)

  • 1. On the interaction between neuroleptics and antiparkinson drugs.
    Julou L
    Mod Probl Pharmacopsychiatry; 1970; 5():50-4. PubMed ID: 5527168
    [No Abstract]   [Full Text] [Related]  

  • 2. Role of brain dopamine in the antipsychotic effect of neuroleptics. Evidence from studies of amphetamine-neuroleptic interaction.
    Randrup A
    Mod Probl Pharmacopsychiatry; 1970; 5():60-5. PubMed ID: 5527170
    [No Abstract]   [Full Text] [Related]  

  • 3. Neurophysiological substrates of the pharmacological criteria for neuroleptics.
    Stille G
    Mod Probl Pharmacopsychiatry; 1970; 5():56-60. PubMed ID: 5527169
    [No Abstract]   [Full Text] [Related]  

  • 4. Chemical and pharmacological classification of neuroleptics.
    Janssen PA
    Mod Probl Pharmacopsychiatry; 1970; 5():33-44. PubMed ID: 5535847
    [No Abstract]   [Full Text] [Related]  

  • 5. Definition and classification of neuroleptics.
    Arnold OH; Collard J; Deniker P; Ginestet D; Hippius H; Itil TM; Labhardt F; Leeds AA; Montanini R; Morozov G; Simon P; Villeneuve A
    Mod Probl Pharmacopsychiatry; 1970; 5():141-7. PubMed ID: 5527163
    [No Abstract]   [Full Text] [Related]  

  • 6. The neuroleptics. 3. Pharmacology. Introduction.
    Van Rossum JM; Janssen PA; Boissier JR; Julou L; Loew DM; Moller Nielsen I; Munkvad I; Randrup A; Stille G; Tedeschi DH
    Mod Probl Pharmacopsychiatry; 1970; 5():23-32. PubMed ID: 5527165
    [No Abstract]   [Full Text] [Related]  

  • 7. [Use in psychiatry of antiparkinson drugs].
    Bourgeois M; Mazaux JM; Imbert D; Daubech MJ; Daulouède JP; Tignol J
    Ann Med Psychol (Paris); 1976 Oct; 2(3):499-510. PubMed ID: 1020859
    [No Abstract]   [Full Text] [Related]  

  • 8. The use of amphetamine induced stereotyped behaviour as a model for the experimental evaluation of antiparkinson agents.
    Costall B; Naylor RJ; Wright T
    Arzneimittelforschung; 1972 Jul; 22(7):1178-83. PubMed ID: 4404343
    [No Abstract]   [Full Text] [Related]  

  • 9. Pimozide, a chemically novel, highly potent and orally long-acting neuroleptic drug. I. The comparative pharmacology of pimozide, haloperidol, and chlorpromazine.
    Janssen PA; Niemegeers CJ; Schellekens KH; Dresse A; Lenaerts FM; Pinchard A; Schaper WK; van Nueten JM; Verbruggen FJ
    Arzneimittelforschung; 1968 Mar; 18(3):261-79. PubMed ID: 4386815
    [No Abstract]   [Full Text] [Related]  

  • 10. [The antiparkinson activity of a new adamantane derivative].
    Val'dman EA; Voronina TA; Nerobkova LN
    Eksp Klin Farmakol; 1999; 62(4):3-6. PubMed ID: 10513325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. On stereotypy and catalepsy: studies on the effect of amphetamines and neuroleptics in rats.
    Fog R
    Acta Neurol Scand Suppl; 1972; 50():3-66. PubMed ID: 4565013
    [No Abstract]   [Full Text] [Related]  

  • 12. [Neuroleptics: functional and biochemical effects].
    Anden NE
    Lakartidningen; 1972 Mar; 69():71-7 passim. PubMed ID: 4664127
    [No Abstract]   [Full Text] [Related]  

  • 13. [Antagonism between anti-Parkinson drugs and neuroleptics. Apropos of various withdrawal experiences, a personal one among them (2nd part)].
    Bourgeois M; Bouey P
    Ann Med Psychol (Paris); 1976 Nov; 2(4):669-708. PubMed ID: 1020864
    [No Abstract]   [Full Text] [Related]  

  • 14. The effect of anti-Parkinson drugs on catalepsy induced by -methyl-p-tyrosine in rats pretreated with intraventricular 6-hydroxydopamine.
    Cashin CH; Sutton S
    Br J Pharmacol; 1973 Mar; 47(3):658P-659P. PubMed ID: 4738385
    [No Abstract]   [Full Text] [Related]  

  • 15. Proceedings: CB 154 (2-bromo-alpha-ergokryptine, bromocriptin), a potential anti-Parkinson agent.
    Johnson AM; Vigouret JM; Loew DM
    Naunyn Schmiedebergs Arch Pharmacol; 1974; 282(Suppl):suppl 282:R40. PubMed ID: 4276573
    [No Abstract]   [Full Text] [Related]  

  • 16. Is it possible to predict the clinical effects of neuroleptic drugs (major tranquillizers) from animal data? IV. An improved experimental design for measuring the inhibitory effects of neuroleptic drugs on amphetamine-or apomorphine-induced "Cheroing" and "agitation" in rats.
    Janssen PA; Niemegeers CJ; Schellekens KH; Lenaerts FM
    Arzneimittelforschung; 1967 Jul; 17(7):841-54. PubMed ID: 5632842
    [No Abstract]   [Full Text] [Related]  

  • 17. [Extra-pyramidal syndrome caused by neuroleptics].
    Lambert PA
    Encephale; 1973; 62(1):78-105. PubMed ID: 4718697
    [No Abstract]   [Full Text] [Related]  

  • 18. Antagonism by neuroleptics of abnormal behavior induced by activation of brain dopamine receptors.
    Van Rossum JM
    Mod Probl Pharmacopsychiatry; 1970; 5():65-7. PubMed ID: 5527171
    [No Abstract]   [Full Text] [Related]  

  • 19. [The antipsychotic action of neuroleptics and basal ganglia function].
    Arushanian EB
    Farmakol Toksikol; 1973; 26(4):481-9. PubMed ID: 4151298
    [No Abstract]   [Full Text] [Related]  

  • 20. The neuroleptics. 10. Therapeutic problems.
    Barahona-Fernandes HJ; Cazzullo CL; Cocchi A; Denber HC; Freyhan FA; Klerman GL; Köknel O; Levine J; Saarma J; Sarteschi P; Vinar O; Wittenborn JR
    Mod Probl Pharmacopsychiatry; 1970; 5():148-56. PubMed ID: 4949818
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.